{"url_path":"/sec/uncy/8-k/2026-06-05/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-065828-index.html","accession_number":"0001213900-26-065828","cik":"0001766140","ticker":"UNCY","issuer_name":"Unicycive Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1766140/0001213900-26-065828-index.html","primary_entity_key":"0001766140","primary_entity_name":"Unicycive Therapeutics, Inc."},"word_count":125,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits.\n\n \n\nExhibit No.\n \nDescription\n\n1.1\n \n[Amendment No. 2 to Sales Agreement, dated June 5, 2026, between Unicycive Therapeutics, Inc. and Guggenheim Securities, LLC (incorporated by reference to Exhibit 1.3 to the Shelf Registration Statement on Form S-3 filed with the Securities and Exchange Commission on June 5, 2026)](https://www.sec.gov/Archives/edgar/data/1766140/000121390026065819/ea029178901ex1-3.htm)\n\n104\n \nCover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document\n\n \n\n1\n\n \n\n \n\n**SIGNATURES**\n\n** **\n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDated: June 5, 2026\n\n \n\n \nUNICYCIVE THERAPEUTICS, INC.\n\n \n \n \n\n \nBy:\n*/s/ Shalabh Gupta*\n\n \nName: \nShalabh Gupta\n\n \nTitle:\nChief Executive Officer\n\n \n\n \n\n2"}